{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:17:11Z","timestamp":1784150231185,"version":"3.55.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.phrs.2024.107557","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T00:43:03Z","timestamp":1735087383000},"page":"107557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Sex-dependent efficacy of sphingosine-1-phosphate receptor agonist FTY720 in mitigating Huntington\u2019s disease"],"prefix":"10.1016","volume":"211","author":[{"given":"Jingyun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Santos-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Eiriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Br\u00fcning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale\u0161","family":"Kvasni\u010dka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Friedeck\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuula A.","family":"Nyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Pahnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.phrs.2024.107557_bib1","first-page":"971","article-title":"The Huntington's Disease Collaborative Research Group","volume":"72","author":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2024.107557_bib2","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"8","key":"10.1016\/j.phrs.2024.107557_bib3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00415-004-0461-9","article-title":"Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study","volume":"251","author":"Lemiere","year":"2004","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.phrs.2024.107557_bib4","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1007\/s00415-015-7900-7","article-title":"Coordinators of the Huntington Study G. Motor onset and diagnosis in Huntington disease using the diagnostic confidence level","volume":"262","author":"Liu","year":"2015","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2024.107557_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105642","article-title":"Recent developments in the management of Huntington's disease","volume":"120","author":"Devadiga","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.phrs.2024.107557_bib7","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.drudis.2022.04.003","article-title":"Repurposing small-molecule drugs for modulating toxic protein aggregates in neurodegenerative diseases","volume":"27","author":"Liu","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.phrs.2024.107557_bib8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ajmg.a.38494","article-title":"Therapy development in Huntington disease: from current strategies to emerging opportunities","volume":"176","author":"Dickey","year":"2018","journal-title":"Am. J. Med Genet A"},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","article-title":"Treatment of Huntington's disease","volume":"11","author":"Frank","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.phrs.2024.107557_bib10","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036525","article-title":"Predictive genetic counseling for neurodegenerative diseases: past, present, and future","volume":"10","author":"Goldman","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med"},{"issue":"23","key":"10.1016\/j.phrs.2024.107557_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314763","article-title":"A novel Huntington's disease assessment platform to support future drug discovery and development","volume":"23","author":"Wu","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13321-023-00775-z","article-title":"HD_BPMDS: a curated binary pattern multitarget dataset of Huntington's disease-targeting agents","volume":"15","author":"Stefan","year":"2023","journal-title":"J. Chemin.-."},{"issue":"2","key":"10.1016\/j.phrs.2024.107557_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.7164\/antibiotics.47.208","article-title":"Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite","volume":"47","author":"Fujita","year":"1994","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"2","key":"10.1016\/j.phrs.2024.107557_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7164\/antibiotics.25.109","article-title":"Myriocin, a new antifungal antibiotic from Myriococcum albomyces","volume":"25","author":"Kluepfel","year":"1972","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"11","key":"10.1016\/j.phrs.2024.107557_bib15","doi-asserted-by":"crossref","first-page":"10284","DOI":"10.1074\/jbc.M412348200","article-title":"Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice","volume":"280","author":"Hojjati","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00007691-200002000-00010","article-title":"The FTY720 story","volume":"22","author":"Napoli","year":"2000","journal-title":"Ther. Drug Monit."},{"issue":"11","key":"10.1016\/j.phrs.2024.107557_bib17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"Pt A","key":"10.1016\/j.phrs.2024.107557_bib18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.phrs.2016.09.025","article-title":"To fingolimod and beyond: the rich pipeline of drug candidates that target S1P signaling","volume":"113","author":"Chew","year":"2016","journal-title":"Pharm. Res"},{"issue":"5","key":"10.1016\/j.phrs.2024.107557_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.12836","article-title":"Sphingosine-1-phosphate receptors and innate immunity","volume":"20","author":"Bryan","year":"2018","journal-title":"Cell Microbiol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","article-title":"Sphingosine-1-phosphate signaling and its role in disease","volume":"22","author":"Maceyka","year":"2012","journal-title":"Trends Cell Biol."},{"issue":"19-20","key":"10.1016\/j.phrs.2024.107557_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202100247","article-title":"Fingolimod effects on the brain are mediated through biochemical modulation of bioenergetics, autophagy, and neuroinflammatory networks","volume":"22","author":"Mirzaei","year":"2022","journal-title":"Proteomics"},{"issue":"3","key":"10.1016\/j.phrs.2024.107557_bib22","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12031-013-9979-6","article-title":"FTY720 (fingolimod) attenuates beta-amyloid peptide (Abeta42)-induced impairment of spatial learning and memory in rats","volume":"50","author":"Asle-Rousta","year":"2013","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2024.107557_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbr.2014.03.046","article-title":"Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid beta-induced memory impairment","volume":"268","author":"Fukumoto","year":"2014","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1096\/fj.201600751r","article-title":"Neuroprotective effects of fingolimod in mouse models of Parkinson's disease","volume":"31","author":"Zhao","year":"2017","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.phrs.2024.107557_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40268-020-00316-1","article-title":"Fingolimod as a treatment in neurologic disorders beyond multiple sclerosis","volume":"20","author":"Bascunana","year":"2020","journal-title":"Drugs R. D."},{"issue":"10306","key":"10.1016\/j.phrs.2024.107557_bib26","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.phrs.2024.107557_bib27","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s12031-014-0423-3","article-title":"Prominence of central sphingosine-1-phosphate receptor-1 in attenuating abeta-induced injury by fingolimod","volume":"54","author":"Asle-Rousta","year":"2014","journal-title":"J. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2024.107557_bib28","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s11064-016-2125-4","article-title":"FTY720 attenuates 6-OHDA-associated dopaminergic degeneration in cellular and mouse Parkinsonian models","volume":"42","author":"Ren","year":"2017","journal-title":"Neurochem Res."},{"issue":"4","key":"10.1016\/j.phrs.2024.107557_bib29","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s13311-016-0462-2","article-title":"Fingolimod: a disease-modifier drug in a mouse model of amyotrophic lateral sclerosis","volume":"13","author":"Potenza","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.phrs.2024.107557_bib30","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s13311-017-0550-y","article-title":"Fingolimod exerts only temporary antiepileptogenic effects but longer-lasting positive effects on behavior in the WAG\/Rij rat absence epilepsy model","volume":"14","author":"Leo","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.phrs.2024.107557_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113120","article-title":"FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in multiple system atrophy mouse models","volume":"325","author":"Vidal-Martinez","year":"2020","journal-title":"Exp. Neurol."},{"issue":"9","key":"10.1016\/j.phrs.2024.107557_bib32","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/hmg\/ddt615","article-title":"FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease","volume":"23","author":"Di Pardo","year":"2014","journal-title":"Hum. Mol. Genet"},{"issue":"17","key":"10.1016\/j.phrs.2024.107557_bib33","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1093\/hmg\/ddv218","article-title":"Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation","volume":"24","author":"Miguez","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.phrs.2024.107557_bib34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1073\/pnas.1014154108","article-title":"FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation","volume":"108","author":"Choi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib35","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1038\/s41598-017-05709-y","article-title":"Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease","volume":"7","author":"Di Pardo","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab303","article-title":"The long and the short of Huntington's disease: how the sphingolipid profile is shifted in the caudate of advanced clinical cases","volume":"4","author":"Phillips","year":"2022","journal-title":"Brain Commun."},{"issue":"6","key":"10.1016\/j.phrs.2024.107557_bib37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4062\/biomolther.2021.012","article-title":"Neuronal autophagy: characteristic features and roles in neuronal pathophysiology","volume":"29","author":"Valencia","year":"2021","journal-title":"Biomol. Ther. (Seoul. )"},{"key":"10.1016\/j.phrs.2024.107557_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.602116","article-title":"Dysfunctional autophagy and endolysosomal system in neurodegenerative diseases: relevance and therapeutic options","volume":"14","author":"Giovedi","year":"2020","journal-title":"Front. Cell. Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2024.107557_bib39","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a020628","article-title":"Astrocytes in neurodegenerative disease","volume":"7","author":"Phatnani","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1152\/physrev.00042.2016","article-title":"Physiology of astroglia","volume":"98","author":"Verkhratsky","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2024.107557_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/B978-0-444-52014-2.00004-5","article-title":"Huntington's disease - neuropathology","volume":"100","author":"Vonsattel","year":"2011","journal-title":"Handb. Clin. Neurol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107557_bib42","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107557_bib43","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1083\/jcb.200508072","article-title":"Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity","volume":"171","author":"Shin","year":"2005","journal-title":"J. Cell Biol."},{"issue":"15","key":"10.1016\/j.phrs.2024.107557_bib44","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/hmg\/ddq212","article-title":"In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects","volume":"19","author":"Faideau","year":"2010","journal-title":"Hum. Mol. Genet"},{"issue":"7","key":"10.1016\/j.phrs.2024.107557_bib45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tins.2017.05.002","article-title":"Unravelling and exploiting astrocyte dysfunction in huntington's disease","volume":"40","author":"Khakh","year":"2017","journal-title":"Trends Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2024.107557_bib46","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s12035-021-02613-5","article-title":"Fingolimod rescues memory and improves pathological hallmarks in the 3xTg-AD model of Alzheimer's disease","volume":"59","author":"Fagan","year":"2022","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107557_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020331","article-title":"Time- and sex-dependent effects of fingolimod treatment in a mouse model of Alzheimer's disease","volume":"13","author":"Bascunana","year":"2023","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.phrs.2024.107557_bib48","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.phrs.2024.107557_bib49","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1093\/hmg\/ddw212","article-title":"An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes","volume":"25","author":"Southwell","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.phrs.2024.107557_bib50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2009.05.007","article-title":"Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models","volume":"35","author":"Menalled","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.phrs.2024.107557_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2024.110239","article-title":"Evaluation of cerebrospinal fluid (CSF) and interstitial fluid (ISF) mouse proteomes for the validation and description of Alzheimer's disease biomarkers","volume":"411","author":"Gorska","year":"2024","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.phrs.2024.107557_bib52","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2007"},{"issue":"2","key":"10.1016\/j.phrs.2024.107557_bib53","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3233\/JAD-201120","article-title":"Machine learning-supported analyses improve quantitative histological assessments of amyloid-beta deposits and activated microglia","volume":"79","author":"Bascunana","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2024.107557_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2021.147579","article-title":"Dimethyl fumarate does not mitigate cognitive decline and beta-amyloidosis in female APPPS1 mice","volume":"1768","author":"Mohle","year":"2021","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.phrs.2024.107557_bib55","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3233\/JAD-200161","article-title":"Early cognitive training rescues remote spatial memory but reduces cognitive flexibility in Alzheimer's disease mice","volume":"75","author":"Rai","year":"2020","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.phrs.2024.107557_bib56","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3233\/JAD-200675","article-title":"Detection and prediction of mild cognitive impairment in Alzheimer's disease mice","volume":"77","author":"Rai","year":"2020","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"10.1016\/j.phrs.2024.107557_bib57","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202154405","article-title":"Isotope-labeled amyloid-beta does not transmit to the brain in a prion-like manner after peripheral administration","volume":"23","author":"Brackhan","year":"2022","journal-title":"EMBO Rep."},{"key":"10.1016\/j.phrs.2024.107557_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2021.109371","article-title":"Development of deep learning models for microglia analyses in brain tissue using DeePathology STUDIO","volume":"364","author":"Mohle","year":"2021","journal-title":"J. Neurosci. Methods"},{"issue":"4","key":"10.1016\/j.phrs.2024.107557_bib59","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3233\/JAD-215180","article-title":"A new tool for the analysis of the effect of intracerebrally injected anti-amyloid-beta compounds","volume":"84","author":"Upite","year":"2021","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40478-017-0448-2","article-title":"Expression of endogenous mouse APP modulates beta-amyloid deposition in hAPP-transgenic mice","volume":"5","author":"Steffen","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib61","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40478-016-0363-y","article-title":"Revisiting rodent models: Octodon degus as Alzheimer's disease model?","volume":"4","author":"Steffen","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"issue":"Pt 8","key":"10.1016\/j.phrs.2024.107557_bib62","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/brain\/awv137","article-title":"Accumulation of murine amyloid-beta mimics early Alzheimer's disease","volume":"138","author":"Krohn","year":"2015","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.phrs.2024.107557_bib63","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2174\/156720511797633179","article-title":"Determination of spatial and temporal distribution of microglia by 230nm-high-resolution, high-throughput automated analysis reveals different amyloid plaque populations in an APP\/PS1 mouse model of Alzheimer's disease","volume":"8","author":"Scheffler","year":"2011","journal-title":"Curr. Alzheimer Res"},{"issue":"12","key":"10.1016\/j.phrs.2024.107557_bib64","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/nprot.2016.136","article-title":"The MaxQuant computational platform for mass spectrometry-based shotgun proteomics","volume":"11","author":"Tyanova","year":"2016","journal-title":"Nat. Protoc."},{"issue":"9","key":"10.1016\/j.phrs.2024.107557_bib65","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nmeth.3901","article-title":"The Perseus computational platform for comprehensive analysis of (prote)omics data","volume":"13","author":"Tyanova","year":"2016","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib66","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1038\/s41467-021-26310-y","article-title":"A metabolome atlas of the aging mouse brain","volume":"12","author":"Ding","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib67","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13075-023-03204-6","article-title":"Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment","volume":"25","author":"Kvasnicka","year":"2023","journal-title":"Arthritis Res Ther."},{"issue":"5","key":"10.1016\/j.phrs.2024.107557_bib68","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acs.analchem.8b05592","article-title":"Systematic error removal using random forest for normalizing large-scale untargeted lipidomics Data","volume":"91","author":"Fan","year":"2019","journal-title":"Anal. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib69","first-page":"21","article-title":"Power comparisons of shapiro-wilk, kolmogorov-smirnov, lilliefors and anderson-darling tests","volume":"2","author":"Razali","year":"2011","journal-title":"J. Stat. Model. Anal."},{"key":"10.1016\/j.phrs.2024.107557_bib70","series-title":"Robust tests for the equality of variance","author":"Levene","year":"1960"},{"issue":"6","key":"10.1016\/j.phrs.2024.107557_bib71","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1460-9568.2005.04324.x","article-title":"Reduction of GnRH and infertility in the R6\/2 mouse model of Huntington's disease","volume":"22","author":"Papalexi","year":"2005","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2024.107557_bib72","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.nbd.2007.01.006","article-title":"Testicular degeneration in Huntington disease","volume":"26","author":"Van Raamsdonk","year":"2007","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2024.107557_bib73","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s13311-017-0565-4","article-title":"Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis","volume":"14","author":"Chaudhry","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.phrs.2024.107557_bib74","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","article-title":"The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis","volume":"30","author":"Hunter","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2024.107557_bib75","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3389\/fnins.2017.00698","article-title":"De novo synthesis of sphingolipids is defective in experimental models of Huntington's disease","volume":"11","author":"Di Pardo","year":"2017","journal-title":"Front Neurosci."},{"key":"10.1016\/j.phrs.2024.107557_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2023.101224","article-title":"Sphingolipids and impaired hypoxic stress responses in Huntington disease","volume":"90","author":"Burtscher","year":"2023","journal-title":"Prog. Lipid Res."},{"issue":"5","key":"10.1016\/j.phrs.2024.107557_bib77","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.tips.2018.02.009","article-title":"The S1P axis: new exciting route for treating Huntington's disease","volume":"39","author":"Di Pardo","year":"2018","journal-title":"Trends Pharm. Sci."},{"issue":"6-7","key":"10.1016\/j.phrs.2024.107557_bib78","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1515\/hsz-2014-0287","article-title":"Subcellular distribution of FTY720 and FTY720-phosphate in immune cells - another aspect of Fingolimod action relevant for therapeutic application","volume":"396","author":"Schroder","year":"2015","journal-title":"Biol. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2024.107557_bib79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib80","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4062\/biomolther.2016.160","article-title":"Sphingosine 1-phosphate receptor modulators and drug discovery","volume":"25","author":"Park","year":"2017","journal-title":"Biomol. Ther. (Seoul. )"},{"issue":"5","key":"10.1016\/j.phrs.2024.107557_bib81","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1476-5381.2009.00451.x","article-title":"FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system","volume":"158","author":"Brinkmann","year":"2009","journal-title":"Br. J. Pharm."},{"issue":"5","key":"10.1016\/j.phrs.2024.107557_bib82","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ana.22426","article-title":"Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis","volume":"69","author":"Cohen","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2024.107557_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.807639","article-title":"Molecular pharmacology and novel potential therapeutic applications of fingolimod","volume":"13","author":"Pournajaf","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107557_bib84","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/978-1-4020-8831-5_15","article-title":"Multiple roles for sphingolipids in steroid hormone biosynthesis","volume":"49","author":"Lucki","year":"2008","journal-title":"Subcell. Biochem"},{"issue":"6","key":"10.1016\/j.phrs.2024.107557_bib85","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.steroids.2010.01.020","article-title":"The interplay between bioactive sphingolipids and steroid hormones","volume":"75","author":"Lucki","year":"2010","journal-title":"Steroids"},{"key":"10.1016\/j.phrs.2024.107557_bib86","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.steroids.2015.10.009","article-title":"Sphingosine-1-phosphate receptor 1 transmits estrogens' effects in endothelial cells","volume":"104","author":"Sukocheva","year":"2015","journal-title":"Steroids"},{"issue":"2","key":"10.1016\/j.phrs.2024.107557_bib87","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0742-8413(99)00065-1","article-title":"Neurosteroid biosynthesis in vertebrate brains","volume":"124","author":"Tsutsui","year":"1999","journal-title":"Comp. Biochem Physiol. C. Pharm. Toxicol. Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib88","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1043-2760(01)00503-3","article-title":"Neurosteroids: biochemistry and clinical significance","volume":"13","author":"Mellon","year":"2002","journal-title":"Trends Endocrinol. Metab.: TEM"},{"issue":"1","key":"10.1016\/j.phrs.2024.107557_bib89","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13293-020-00326-3","article-title":"Sex differences in brain atrophy in multiple sclerosis","volume":"11","author":"Voskuhl","year":"2020","journal-title":"Biol. Sex. Differ."},{"issue":"10","key":"10.1016\/j.phrs.2024.107557_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.804","article-title":"Gender differences in safety issues during Fingolimod therapy: evidence from a real-life Relapsing Multiple Sclerosis cohort","volume":"7","author":"Manni","year":"2017","journal-title":"Brain Behav."},{"key":"10.1016\/j.phrs.2024.107557_bib91","article-title":"Acute treatment with fingolimod does not confer long-term benefit in a mouse model of intracerebral haemorrhage","volume":"11","author":"Diaz Diaz","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107557_bib92","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4161\/auto.6.8.13614","article-title":"FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy","volume":"6","author":"Zhang","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.phrs.2024.107557_bib93","doi-asserted-by":"crossref","DOI":"10.1038\/srep24939","article-title":"Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease","volume":"6","author":"Aytan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2024.107557_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135250","article-title":"Fingolimod administration improves neurological functions of mice with subarachnoid hemorrhage","volume":"736","author":"Wang","year":"2020","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.phrs.2024.107557_bib95","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ana.24217","article-title":"Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide","volume":"76","author":"Colombo","year":"2014","journal-title":"Ann. Neurol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824005024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824005024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:48:52Z","timestamp":1736430532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824005024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":95,"alternative-id":["S1043661824005024"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107557","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex-dependent efficacy of sphingosine-1-phosphate receptor agonist FTY720 in mitigating Huntington\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107557"}}